Big Pharma Acquisitions Replaced Biotech IPOs in 2026
Large pharmaceutical companies increasingly acquired startups instead of allowing firms to pursue public markets.
Updated on Sept. 25, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical company acquisitions of biotech startups lead to better medical innovation?
Throughout 2026, the biotechnology sector saw a shift toward corporate acquisition as the primary exit strategy for startups. This trend represents a notable decline in initial public offerings, which raised $3 billion in 2025 compared to $4 billion in 2023.
Why it matters
The shift occurs as startups increasingly require mature commercial infrastructure to scale, while major pharmaceutical firms rely on these acquisitions to secure specialized innovation. This consolidation of R&D pipelines enables larger entities to internalize high-risk research in cell and gene therapy.
Major deals in 2026 included Bristol Myers Squibb's $1.5 billion acquisition of Orbital Therapeutics and AbbVie’s $2.1 billion purchase of Capstan Therapeutics. Eli Lilly, which reported $65 billion in 2025 revenue and projects $90 billion for 2026, aggressively expanded its pipeline with a $3.25 billion upfront deal for Kelonia Therapeutics.
The players
Eli Lilly
A pharmaceutical giant focusing on global drug distribution and a expanding portfolio in cell and gene therapy.
Gilead Sciences
A research-based biopharmaceutical firm known for its early and significant moves into the CAR-T cell therapy market.
AstraZeneca
A global pharmaceutical corporation that maintains a diverse pipeline of specialty medications and biotechnology assets.
AbbVie
A large-scale pharmaceutical company currently integrating specialized biotechnology platforms for targeted therapy development.
Bristol Myers Squibb
An international biopharmaceutical company focused on oncology and immunology research through strategic acquisitions.
The details
Pharmaceutical companies acquire biotechnology firms by absorbing their research platforms and specialized skill sets into existing commercial pipelines. This mechanism allows firms to bypass the regulatory and capital-intensive hurdles of the public market, which historically served as the primary pathway for biotech growth. For instance, Eli Lilly utilizes its substantial revenue to consolidate cell and gene therapy developers, effectively integrating early-stage experimental technologies into its global distribution networks.
Timeline
2016: Astellas acquired Ocata Therapeutics.
2017: Gilead Sciences acquired Kite Pharma for $11.9 billion.
2023: Biotech IPOs raised $4 billion in total capital.
2025: Biotech IPOs raised $3 billion in total capital.
2026: Pharmaceutical M&A activity accelerated within the cell and gene therapy sector.
The Tech Race
The current wave of acquisitions reflects a strategy similar to the precedent set by Gilead Sciences' 2017 acquisition of Kite Pharma. These deals effectively extend the competitive landscape by shifting the focus from public market capitalization to the consolidation of R&D pipelines within established corporate giants.
The shift toward acquisition potentially accelerates the time-to-market for specialized therapies, as startups gain access to the manufacturing and regulatory expertise of larger firms. Patients may see fewer biotech companies as independent entities, as these innovations are increasingly integrated into the branded portfolios of global pharmaceutical corporations.
The takeaway
The move away from IPOs suggests that large pharmaceutical firms are prioritizing internal pipeline consolidation over independent market competition. Investors should track future revenue projections and acquisition costs to determine if this growth model can sustain long-term innovation in gene therapy.
Further reading
For broader trends in industry research and corporate strategy, see Biotech.
Source note: This article includes information reported by BioXconomy.
Live Poll
Do you trust that pharmaceutical company acquisitions of biotech startups lead to better medical innovation?
